Integra LifeSciences/$IART
IART rises after Q2 revenues beat guidance and adj. EPS topped expectations while completing assessments under its Compliance Master Plan following an FDA warning letter.
1 hour ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Integra LifeSciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Ticker
$IART
Sector
Primary listing
Employees
4,396
Headquarters
Website
IART Metrics
BasicAdvanced
$1.1B
-
-$6.54
1.17
-
Price and volume
Market cap
$1.1B
Beta
1.17
52-week high
$27.13
52-week low
$11.06
Average daily volume
1.3M
Financial strength
Current ratio
1.229
Quick ratio
0.579
Long term debt to equity
133.537
Total debt to equity
194.07
Interest coverage (TTM)
1.97%
Profitability
EBITDA (TTM)
305.189
Gross margin (TTM)
57.52%
Net profit margin (TTM)
-30.87%
Operating margin (TTM)
9.23%
Effective tax rate (TTM)
10.41%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
2.48%
Return on equity (TTM)
-38.92%
Valuation
Price to revenue (TTM)
0.645
Price to book
1.03
Price to tangible book (TTM)
-1.39
Price to free cash flow (TTM)
-22.093
Free cash flow yield (TTM)
-4.53%
Free cash flow per share (TTM)
-0.619
Growth
Revenue change (TTM)
3.53%
Earnings per share change (TTM)
-2,292.09%
3-year revenue growth (CAGR)
1.15%
10-year revenue growth (CAGR)
6.96%
3-year earnings per share growth (CAGR)
49.18%
10-year earnings per share growth (CAGR)
26.86%
What the Analysts think about IART
Analyst ratings (Buy, Hold, Sell) for Integra LifeSciences stock.
IART Financial Performance
Revenues and expenses
IART Earnings Performance
Company profitability
IART News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Integra LifeSciences stock?
Integra LifeSciences (IART) has a market cap of $1.1B as of August 22, 2025.
What is the P/E ratio for Integra LifeSciences stock?
The price to earnings (P/E) ratio for Integra LifeSciences (IART) stock is 0 as of August 22, 2025.
Does Integra LifeSciences stock pay dividends?
No, Integra LifeSciences (IART) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Integra LifeSciences dividend payment date?
Integra LifeSciences (IART) stock does not pay dividends to its shareholders.
What is the beta indicator for Integra LifeSciences?
Integra LifeSciences (IART) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.